证券代码：301246 证券简称：宏源药业 公告编号：2023-045 湖北省宏源药业科技股份有限公司 关于取消 2023 年第四次临时股东大会部分提案 暨召开 2023 年第四次临时股东大会补充通知的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 湖北省宏源药业科技股份有限公司（以下简称"公司"）于2023年8月29日 召开了第四届董事会第二次会议，审议通过《关于变更部分募集资金用途并使 用超募资金投资建设新项目的议案》，并提交于2023年9月18日（星期三） 14:30召开的2023年第四次临时股东大会审议，具体内容详见公司于2023年8月 31日披露于巨潮资讯网（www.cninfo.com.cn）的《关于变更部分募集资金用途 并使用超募资金投资建设新项目的公告》（公告编号：2023-040）。 近日，公司管理层再研究讨论，认为长远来看，募投项目抗病毒原料药及 中间体项目仍具有发展前景，未来仍希望择机启动该项目的建设。基于此，为 确保募集资金使用合法、安全、有效，实现公司和全体股东利益的最大化，经 公司管理层审慎 ...

深 圳 证 券 交 易 所 关于对湖北省宏源药业科技股份有限公司 的关注函 创业板关注函〔2023〕第 283 号 湖北省宏源药业科技股份有限公司董事会： 2023 年 8 月 30 日，你公司披露《2023 年度半年报》（以 下简称半年报）以及《关于变更部分募集资金用途并使用超 募资金投资建设新项目的公告》（以下简称募集资金变更公 告）等公告。 1.半年报显示，报告期，归属于上市公司股东的净利润 （以下简称净利润）为 6,502.34 万元，同比下滑 78.51%，分 季度看，第一季度、第二季度分别实现净利润 6,474.44 万 元和 27.91 万元；经营活动产生的现金流量净额（以下简称 经营性现金流净额）为-11,028.39 万元，同比下滑 198.11%。 （1）半年报显示，"公司净利润较去年同期大幅下降主 要受六氟磷酸锂业务影响"。请结合同行业可比上市公司情 况，说明公司业绩变动是否符合行业以及季度变化趋势。 1 （2）半年报显示，经营性现金流净额大幅下滑"主要是 购买商品、接受劳务支付的现金较上期增加所致"。请结合 你公司购买产品或服务的类别、成本构成及其变化等情况， 量化分析报告期经营性现金 ...

Financial Position - Total assets increased to ¥5,685,463,995.12, up from ¥3,848,818,212.18, representing a growth of approximately 47.8%[25] - Current assets totaled ¥3,771,343,234.56, compared to ¥1,807,735,806.76 in the previous period, indicating a rise of about 108.5%[25] - Non-current assets decreased to ¥1,914,120,760.56 from ¥2,041,082,405.42, reflecting a decline of approximately 6.2%[25] - The total assets of Hubei Hongyuan Pharmaceutical Technology Co., Ltd. reached CNY 5,709,791,741.00 as of June 30, 2023, compared to CNY 3,874,152,752.16 at the end of the previous period[47] - The company's non-current assets totaled CNY 2,160,590,689.47, slightly down from CNY 2,209,229,490.49[47] - The total owner's equity at the end of the period was 352,749,600.00 RMB[81] - The total equity attributable to owners is 756.00 million RMB, reflecting a stable financial position[84] Cash Flow and Investments - The company reported a net cash outflow from investing activities of ¥1,845,985,184.25, compared to a net outflow of ¥231,474,524.37 in the previous period[29] - Cash and cash equivalents at the end of the period were ¥60,035,607.52, down from ¥309,451,948.16, a decrease of about 80.6%[29] - The company reported an investment loss of -6,553,228.17, a significant drop from the previous period's gain of 143,114,763.04[53] Liabilities - The total liabilities included short-term borrowings of ¥7,630,072.00, with accounts payable at ¥320,153,389.92, down from ¥417,543,545.94, a decrease of about 23.3%[25] - The total liabilities include short-term borrowings of CNY 17,642,065.09 and accounts payable of CNY 359,968,710.88[47] - The company reported a decrease in accounts payable from CNY 456,605,437.21 to CNY 359,968,710.88, indicating a reduction of approximately 21.2%[47] Profit and Loss - The net profit for the current period is 65,023,439.88, a decrease from 302,536,958.56 in the previous period, representing a decline of approximately 78.5%[51] - The total profit for the current period is 76,092,913.33, down from 333,497,999.30, indicating a decrease of about 77.2%[51] - The basic earnings per share decreased to 0.1709 from 0.7949, a decline of approximately 78.5%[51] - The total comprehensive income attributable to the parent company's owners is 65,023,439.88, down from 302,536,958.56, reflecting a decrease of about 78.5%[51] Expenses - Research and development expenses increased to 26,571,327.70 from 25,925,032.70, reflecting a rise of approximately 2.5%[50] - The interest expense for the current period is 5,296,841.83, significantly higher than 1,314,854.87 in the previous period, marking an increase of about 302.5%[50] - The sales expenses for the current period are 17,863,131.92, slightly down from 18,136,364.40, indicating a decrease of about 1.5%[50] - The tax expenses for the current period are 11,069,473.45, compared to 30,961,040.74 in the previous period, showing a decrease of approximately 64.3%[50] Shareholder Information - The company’s major shareholders include Yan Xiaohui with 22.15% and Yin Guoping with 16.04% of shares[17] - The company has a total of 352,749,600 shares, with 102,986,836 shares held by other pre-IPO shareholders[37] Corporate Governance - The company did not report any significant legal disputes or contingent liabilities during the reporting period[5] - There were no significant changes in the company’s registered address or contact information during the reporting period[27] - The company has not undergone an audit for the semi-annual financial report[45] - The report indicates that the company has terminated its listing on the National Equities Exchange and Quotations system as of February 21, 2023[35] Future Outlook and Strategy - The company has not disclosed any new product developments or market expansion strategies in the report[49] - The company is focusing on the development of new products and technologies to enhance its market position[97] - The company is actively exploring market expansion strategies to increase its market share in the pharmaceutical sector[97] - The company plans not to distribute cash dividends or issue bonus shares, indicating a focus on reinvestment[95] Accounting Policies - The financial statements were prepared based on the going concern assumption in accordance with the relevant accounting standards[83] - The financial statements are prepared based on the accrual basis of accounting, ensuring accurate representation of financial performance[99] - The financial report includes specific accounting policies and estimates, ensuring compliance with relevant accounting standards[124] Risk Management - The company has not reported any significant risks that could impact its operations in the near term[94] - The company has confirmed its ability to continue as a going concern for at least the next 12 months[100]

证券代码： 301246 证券简称：宏源药业 湖北省宏源药业科技股份有限公司 投资者关系活动记录表 编号：2023-002 投资者关系活动 □特定对象调研 □ 分析师会议 类别 □ 媒体采访 □ 业绩说明会 □ 新闻发布会 □ 路演活动 □ 现场参观 √ 其他（2023 年湖北辖区上市公司投资者网上集体接待日活动） 参与单位名称及 参与 2023 年湖北辖区上市公司投资者网上集体接待日活动的投 人员姓名 资者 时间 2023 年 5 月 25 日 (周四) 下午 14:30~16:35 地点 全景网"投资者关系互动平台"（https://ir.p5w.net） 上市公司接待人 1、副董事长、董事会秘书尹聃 员姓名 2、财务负责人曾科峰 3、总监肖拥华 投资者提出的问题及公司回复情况 公司就投资者在本次说明会中提出的问题进行了回复： 1、请问公司 2022 年锂电池材料的收入大幅增长的原因 是？ 答：尊敬的投资者，您好。2022 年受年产 1,000 吨六氟磷 酸锂生产装置技术改造项目、年产 6,000 吨六氟磷酸锂建设项 目陆续投入试生产影响，公司六氟磷酸锂产销量增加，相应六 投资者关系活动 主要内容介绍 氟 ...

证券代码： 301246 证券简称：宏源药业 公告编号： 2023-035 湖北省宏源药业科技股份有限公司 关于参加2023年湖北辖区上市公司投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，湖北省宏源药业科技股份有限公司(以 下简称"公司") 将参加由湖北证监局、湖北省上市公司协会和深圳市全景网络 有限公司联合举办的"提高发展质量 切实回报股东——2023 年湖北辖区上市公 司投资者网上集体接待日"活动，现将有关事项公告如下： 本次集体接待日活动通过线上形式举行，投资者可登录"全景路演" ( http://rs.p5w.net )参与本次交流互动，具体交流互动的时间为 2023 年 5 月 25 日 (周四) 14:30-16:35。届时，公司副董事长、董事会秘书尹聃先生、财务负责人曾 科峰先生、总监肖拥华先生将在线就投资者关心的问题，与投资者进行沟通交流， 欢迎广大投资者踊跃参与！ 特此公告。 湖北省宏源药业科技股份有限公司董事会 2023 年 5 月 24 日 ...

证券代码：301246 证券简称：宏源药业 湖北省宏源药业科技股份有限公司 投资者关系活动记录表 编号：2023-001 投资者关系活动类别 ☐特定对象调研 ☐分析师会议 ☐媒体采访 业绩说明会 ☐新闻发布会 ☐路演活动 ☐现场参观 ☐其他（请文字说明其他活动内容） 参与单位名称及人员姓名 通过价值在线（https://www.ir-online.cn/）参与公司2022年度 网上业绩说明会的投资者 时间 2023年05月18日 15:30-17:00 地点 价值在线（https://www.ir-online.cn/） 董事长 尹国平先生 董事会秘书 尹聃先生 财务总监 曾科峰先生 上市公司接待人员姓名 总监 肖拥华先生 独立董事 谢青先生 保荐代表人 谢广化先生 投资者关系活动主要内容 1.请问公司2022年业绩情况如何？ 答:您好，公司全年实现营业收入206,372.35万元，较2021年增 长30.79%；实现利润总额47,797.64万元，归属于上市公司股东的净 利润43,479.56万元。感谢您对公司的关注。 介绍 2.请问公司2022年营业收入较上年上涨30%，但净利润却同比下 降，其主要原因是 ...

Financial Performance - The company's operating revenue for 2022 was ¥2,063,723,485.64, representing a 30.79% increase compared to ¥1,577,859,433.57 in 2021[21] - The net profit attributable to shareholders decreased by 11.96% to ¥434,795,621.19 in 2022 from ¥493,849,962.45 in 2021[21] - The net profit after deducting non-recurring gains and losses was ¥406,490,298.68, down 16.25% from ¥485,385,724.29 in the previous year[21] - The basic earnings per share for 2022 were ¥1.23, a decrease of 12.14% from ¥1.40 in 2021[21] - The weighted average return on net assets was 22.93%, down from 34.51% in the previous year[21] - The net cash flow from operating activities increased by 9.63% to ¥214,987,266.74 in 2022 from ¥196,095,182.26 in 2021[21] Assets and Liabilities - The total assets at the end of 2022 reached ¥3,874,152,752.16, a 59.28% increase from ¥2,432,256,726.66 at the end of 2021[21] - The net assets attributable to shareholders increased by 25.98% to ¥2,113,844,051.04 at the end of 2022 from ¥1,677,983,351.71 at the end of 2021[21] - The company’s long-term borrowings rose to CNY 341,669,000.00, representing an increase of 6.88% in its proportion of total liabilities[71] Market and Industry Trends - The pharmaceutical industry in China achieved a total revenue of CNY 2,911.14 billion in 2022, with a profit of CNY 428.87 billion, indicating a stable growth trend[32] - The lithium battery industry is projected to see a compound annual growth rate of 25.6%, with global shipments expected to reach 5 TWh by 2030[34] - The company aims to expand its international market presence and enhance its product pipeline, focusing on high-end APIs and specialty intermediates[33] Production and Capacity - The company has increased its lithium hexafluorophosphate production capacity to 8,000 tons per year, significantly enhancing its market competitiveness[34] - The company has a design capacity of 61,480 tons for pharmaceutical manufacturing with a utilization rate of 89.71%[39] - The chemical manufacturing sector has a design capacity of 121,000 tons with a utilization rate of 93.31% and an additional 7,000 tons/year under construction[39] Research and Development - The company has a strong focus on R&D, with core technologies recognized as domestically leading or internationally advanced[43] - The company’s R&D expenses rose by 31.40% to ¥64,009,857.78 in 2022, compared to ¥48,712,343.26 in 2021, reflecting increased investment in R&D projects[63] - The number of R&D personnel increased by 21.29% to 188, with a notable rise in younger employees under 30 years old, which increased by 116.67%[67] Risk Factors - The company has indicated potential risks in its future development outlook, which investors should be aware of[4] - The company faces risks from fluctuations in raw material prices, which could impact gross margins if not adjusted timely[86] - There is a risk of product price decline due to macroeconomic changes and industry capacity expansion, potentially affecting profitability[87] Governance and Compliance - The company has established a robust governance structure, ensuring compliance with relevant laws and regulations[96] - The company maintains complete independence from its controlling shareholders in terms of assets, personnel, finance, organization, and business operations, meeting regulatory requirements for independence[103] - The company has a comprehensive quality control system, but lapses in execution could harm market reputation and operations[91] Social Responsibility and Environmental Impact - The company actively participates in social responsibility initiatives, including support for disadvantaged groups and local employment[166] - The company has implemented environmental impact assessments for all construction projects as per legal requirements[154] - The company invested a total of CNY 169,657,621.43 in environmental protection, including CNY 124,097,299.77 in capitalized investments and CNY 45,560,321.66 in expenses[158] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 723[200] - The largest shareholder, Yan Xiaohui, holds 25.11% of the shares, totaling 88,585,200 shares[200] - The company distributed a cash dividend of 1.00 RMB per 10 shares, totaling 40,000,680.00 RMB, which represents 100% of the total profit distribution[143]

| --- | --- | --- | |------------------------|------------------|-------------------| | 项目 | 期末余额 | 年初余额 单位：元 | | 流动资产： | | | | 货币资金 | 2,476,954,474.29 | 395,191,497.27 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | | | | 衍生金融资产 | | | | 应收票据 | 134,608,878.55 | 182,187,412.53 | | 应收账款 | 213,615,349.06 | 313,737,651.98 | | 应收款项融资 | 263,106,286.59 | 164,279,985.64 | | 预付款项 | 25,037,830.07 | 18,848,631.88 | | 应收保费 | | | | 应收分保账款 | | | | 应收分保合同准备金 | | | | | | | | 其他应收款 | 199,611,108.37 | 87,595,665.56 | | 其中：应收利息 | | ...

证券代码：301246 证券简称：宏源药业 公告编号：2023-026 湖北省宏源药业科技股份有限公司 关于举办2022年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 投资者可于 2023 年 5 月 18 日（星期四） 15:30-17:00 通过网址 https://eseb.cn/14c8ivUKEI8 或使用微信扫描下方小程序码即可进入参与互动交 流。投资者可于 2023 年 5 月 18 日前进行会前提问，公司将通过本次业绩说明 会，在信息披露允许范围内就投资者普遍关注的问题进行回答。 四、联系人及咨询办法 湖北省宏源药业科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 28 日在巨潮资讯网（www.cninfo.com.cn）上披露了《2022 年年度报告全文》及 《2022 年年度报告摘要》。为便于广大投资者更加全面深入地了解公司经营业 绩、发展战略等情况，公司定于 2023 年 5 月 18 日（星期四）15:30-17:00 在"价 值在线"（www.ir-online.cn）举办公司 ...

股票简称：宏源药业 股票代码：301246 湖北省宏源药业科技股份有限公司 Hubei Hongyuan Pharmaceutical Technology Co., Ltd. （湖北省罗田县凤山镇经济开发区宏源路8号） 首次公开发行股票并在创业板上市 之 上市公告书 保荐人（主承销商） （中国（上海）自由贸易试验区浦明路 8 号） 二零二三年三月 特别提示 湖北省宏源药业科技股份有限公司（以下简称"宏源药业"、"本公司"或 "发行人"、"公司"）股票将于 2023 年 3 月 20 日在深圳证券交易所创业板上 市，该市场具有较高的投资风险。创业板公司具有业绩不稳定、经营风险高、退 市风险大等特点，投资者面临较大的市场风险。投资者应充分了解创业板市场的 投资风险及本公司所披露的风险因素，审慎做出投资决定。 本公司提醒投资者应充分了解股票市场风险以及本公司披露的风险因素，在 新股上市初期切忌盲目跟风"炒新"，应当审慎决策、理性投资。 如无特别说明，本上市公告书中的简称或名词的释义与本公司首次公开发行 股票并在创业板上市招股说明书中的相同。 1 | 特别提示 1 | | --- | | 目 录 2 | | 第一节 ...